LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7.2% - Here's Why

LB Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • LB Pharmaceuticals shares fell 7.2% to about $39.90, with trading volume 49% below its average.
  • The company reported a quarterly loss of $1.79 per share, missing analysts’ expected loss of $1.61 per share.
  • Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and a $57.40 average price target, despite Roth Capital downgrading the stock to “neutral.”
  • Five stocks we like better than LB Pharmaceuticals.

Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report) were down 7.2% on Tuesday. The company traded as low as $40.04 and last traded at $39.8950. 152,074 shares traded hands during trading, a decline of 49% from the average session volume of 296,077 shares. The stock had previously closed at $42.99.

Analyst Ratings Changes

LBRX has been the subject of several analyst reports. Needham & Company LLC started coverage on shares of LB Pharmaceuticals in a report on Friday, October 2nd. They set a "buy" rating and a $68.00 price target for the company. Guggenheim reissued a "buy" rating on shares of LB Pharmaceuticals in a research report on Monday, October 12th. Canaccord Genuity Group started coverage on LB Pharmaceuticals in a research note on Friday, October 9th. They issued a "buy" rating and a $65.00 target price on the stock. Raymond James Financial upgraded LB Pharmaceuticals to a "buy" rating in a report on Monday, October 12th. Finally, Roth Capital lowered LB Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $37.00 to $35.00 in a research report on Monday, October 5th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.40.

Get Our Latest Report on LB Pharmaceuticals

LB Pharmaceuticals Stock Performance

The company has a market cap of $1.29 billion, a P/E ratio of -8.53 and a beta of 0.82. The stock has a 50-day moving average of $40.06 and a two-hundred day moving average of $33.59.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($1.79) earnings per share for the quarter, missing analysts' consensus estimates of ($1.61) by ($0.18). Research analysts predict that LB Pharmaceuticals Inc will post -6.05 EPS for the current year.

Institutional Investors Weigh In On LB Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aquatic Capital Management LLC raised its stake in LB Pharmaceuticals by 311.9% during the 3rd quarter. Aquatic Capital Management LLC now owns 24,530 shares of the company's stock worth $941,000 after acquiring an additional 18,574 shares during the period. Goldman Sachs Group Inc. increased its position in LB Pharmaceuticals by 67.3% in the third quarter. Goldman Sachs Group Inc. now owns 964,373 shares of the company's stock worth $37,013,000 after purchasing an additional 387,917 shares during the last quarter. Great Point Partners LLC raised its position in shares of LB Pharmaceuticals by 29.4% during the 3rd quarter. Great Point Partners LLC now owns 410,420 shares of the company's stock valued at $15,752,000 after buying an additional 93,199 shares in the last quarter. Bellevue Group AG bought a new stake in shares of LB Pharmaceuticals in the 3rd quarter valued at approximately $27,461,000. Finally, Integral Health Asset Management LLC lifted its position in LB Pharmaceuticals by 213.3% in the third quarter. Integral Health Asset Management LLC now owns 470,000 shares of the company's stock worth $18,039,000 after buying an additional 320,000 shares during the last quarter.

About LB Pharmaceuticals

(Get Free Report)

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for serious neuropsychiatric disorders. Its research focuses on medicines intended to address conditions with significant unmet treatment needs. The company's lead candidate, LB-102, is an oral investigational drug being studied for schizophrenia. LB Pharmaceuticals has also identified other psychiatric conditions, including bipolar disorder, as potential areas of development. LB-102 has not been approved for commercial use, and its safety and effectiveness have not been established by regulators.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LB Pharmaceuticals Right Now?

Before you consider LB Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LB Pharmaceuticals wasn't on the list.

While LB Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines